07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Beijing Jialin, Luye deal

Luye Pharma terminated its proposed acquisition of a majority stake in Beijing Jialin. The company did not disclose reasons for terminating the acquisition, which was contingent on several conditions. Beijing Jialin markets drugs for cancer...
00:22 , Jun 3, 2015 |  BC Extra  |  Company News

Luye terminates equity deal with Beijing Jialin

Luye Pharma Group Ltd. (HKSE:2186) terminated its proposed acquisition of a majority stake in Beijing Jialin Pharmaceutical Co. Ltd. (Beijing, China). The company did not disclose reasons for terminating the acquisition, which was contingent on...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Beijing Jialin, Pfizer cardiovascular news

China’s Supreme People’s Court ruled invalid a patent covering crystalline formulations of Pfizer’s Lipitor atorvastatin, preventing the pharma from suing generic makers. The court said patent application CN96195564.3 did not provide sufficient detail to support...
02:17 , May 8, 2015 |  BC Extra  |  Company News

China's top court invalidates Lipitor patent

China's Supreme People's Court ruled invalid a patent covering crystalline formulations of Lipitor atorvastatin from Pfizer Inc. (NYSE:PFE), preventing it from suing generic makers and opening the door to additional competition that could erode the...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Beijing Jialin, Luye deal

Luye Pharma will pay RMB3.7 billion ($599 million) in a tranched cash deal to acquire a 57.98% stake in Beijing Jialin, a subsidiary of Mylin Holdings Group Co. Ltd., from Mylin Holdings and Beijing CITIC....
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
01:18 , Aug 29, 2014 |  BC Extra  |  Company News

Luye buys majority stake in Beijing Jialin

Luye Pharma Group Ltd. (HKSE:2186) will acquire a 58% stake in Beijing Jialin Pharmaceutical Co. Ltd. from Beijing Jialin shareholders Mylin Holding Group Co. Ltd. (Beijing, China) and Beijing CITIC in a tranched RMB3.7 billion...